279 related articles for article (PubMed ID: 16849577)
1. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
Kocak E; Lute K; Chang X; May KF; Exten KR; Zhang H; Abdessalam SF; Lehman AM; Jarjoura D; Zheng P; Liu Y
Cancer Res; 2006 Jul; 66(14):7276-84. PubMed ID: 16849577
[TBL] [Abstract][Full Text] [Related]
2. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
3. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
4. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
5. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
[TBL] [Abstract][Full Text] [Related]
7. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
8. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.
Melero I; Johnston JV; Shufford WW; Mittler RS; Chen L
Cell Immunol; 1998 Dec; 190(2):167-72. PubMed ID: 9878117
[TBL] [Abstract][Full Text] [Related]
9. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.
Arribillaga L; Sarobe P; Arina A; Gorraiz M; Borrás-Cuesta F; Ruiz J; Prieto J; Chen L; Melero I; Lasarte JJ
Vaccine; 2005 May; 23(27):3493-9. PubMed ID: 15855007
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy.
Choi BK; Kim YH; Kang WJ; Lee SK; Kim KH; Shin SM; Yokoyama WM; Kim TY; Kwon BS
Cancer Res; 2007 Sep; 67(18):8891-9. PubMed ID: 17875731
[TBL] [Abstract][Full Text] [Related]
12. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.
Gregor PD; Wolchok JD; Ferrone CR; Buchinshky H; Guevara-Patiño JA; Perales MA; Mortazavi F; Bacich D; Heston W; Latouche JB; Sadelain M; Allison JP; Scher HI; Houghton AN
Vaccine; 2004 Apr; 22(13-14):1700-8. PubMed ID: 15068853
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with agonistic anti-CD137: two sides of a coin.
Sun Y; Chen JH; Fu Y
Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
[TBL] [Abstract][Full Text] [Related]
14. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
15. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity.
Ko E; Luo W; Peng L; Wang X; Ferrone S
Cancer Res; 2007 Aug; 67(16):7875-84. PubMed ID: 17699794
[TBL] [Abstract][Full Text] [Related]
16. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
17. 4-1BB-mediated immunotherapy of rheumatoid arthritis.
Seo SK; Choi JH; Kim YH; Kang WJ; Park HY; Suh JH; Choi BK; Vinay DS; Kwon BS
Nat Med; 2004 Oct; 10(10):1088-94. PubMed ID: 15448685
[TBL] [Abstract][Full Text] [Related]
18. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance.
Foell JL; Diez-Mendiondo BI; Diez OH; Holzer U; Ruck P; Bapat AS; Hoffmann MK; Mittler RS; Dannecker GE
Immunology; 2004 Sep; 113(1):89-98. PubMed ID: 15312139
[TBL] [Abstract][Full Text] [Related]
19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
Cuadros C; Dominguez AL; Lollini PL; Croft M; Mittler RS; Borgström P; Lustgarten J
Int J Cancer; 2005 Oct; 116(6):934-43. PubMed ID: 15856473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
